Allianz’s BioMarin Pharmaceuticals BMRN Stock Holding History

Allianz’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.2M	Hold	73,400	–	–	0.04%	212
2026 Q1	$4.15M	Buy	73,400 +28,400	+63%	+$1.66M	0.05%	200
2025 Q4	$2.67M	Hold	45,000	–	–	0.03%	191
2025 Q3	$2.44M	Hold	45,000	–	–	0.05%	176
2025 Q2	$2.47M	Hold	45,000	–	–	0.06%	168
2025 Q1	$3.18M	Sell	45,000 -1,830	-4%	-$123K	0.08%	153
2024 Q4	$3.07M	Hold	46,830	–	–	0.08%	145
2024 Q3	$3.29M	Buy	+46,830	New	+$3.91M	0.09%	138

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Allianz's BMRN Position: Q2 2026 in Review

Allianz held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2026 at 73,400 shares worth $4.2M. The position accounts for 0.04% of the portfolio, ranked #212.

Allianz first reported a position in BMRN in Q3 2024 and has held it in 8 quarters since. 564 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Allianz held 73,400 shares of BioMarin Pharmaceuticals worth $4.2M as of Q2 2026.
Allianz left its BioMarin Pharmaceuticals share count unchanged in Q2 2026.
BioMarin Pharmaceuticals made up 0.04% of Allianz's portfolio in Q2 2026, its #212 holding.
Allianz first reported a position in BioMarin Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
564 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Allianz's 13F filing for Q2 2026, filed 10 Aug 2026.